Table 1.
Patients, n = 33 | Value |
---|---|
Age (years) | |
Median | 70 |
Range | 53-82 |
ECOG performance status, n (%) | |
0 | 23 (69.6) |
1 | 5 (15.2) |
2 | 5 (15.2) |
Gleason score at diagnosis, n (%) | |
Unknown | 3 (9.1) |
≤ 7 | 11 (33.3) |
≥ 8 | 19 (57.6) |
Primary therapy, n (%) | |
RP | 9 (27.3) |
EBRT | 4 (12.1) |
Palliative | 20 (60.6) |
Metastatic sites, n (%) | |
Soft tissue | 3 (9.0) |
Bone + LN | 15 (45.5) |
Bone + Visceral ± LN | 15 (45.5) |
Biochemical markersa | |
PSA [ng/dl] | 140 |
0.1-3378 | |
Lactate dehydrogenase [U/l] | 320 |
218-1900 | |
Alkaline phosphatase [U/l] | 164 |
50-1466 | |
Hemoglobin [g/dl] | 11.6 |
8.5-16.1 |
ECOG, eastern cooperative oncology group; EBRT, external beam radiotherapy; LN, lymph node metastases; PSA, prostate-specific antigen; RP, radical prostatectomy; n, number
avalues given as median and range